Recent studies have identified a novel IgE–mast cell (MC)–IL-6–endothelial dysfunction pathway in the pathophysiology of hypertension, providing a rationale for investigating anti-IgE interventions [128]. This evidence concerns the gene IGHE and hypertensive disorder.